杭州啓明醫療器械股份有限公司 Venus Medtech (Hangzhou) Inc. (A joint stock company incorporated in the People's Republic of China with limited liability) (Stock Code: 2500) ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2022 The board (the "Board") of directors (the "...
If you have sold or transferred all your shares in Venus Medtech (Hangzhou) Inc., you should at once hand this circular and the accompanying proxy form(s) to the purchaser or transferee or to the bank, licensed securities dealer or other agent through whom the sale or transfer was ...
The Board will meet several times a year at Venus Medtech's offices inChinaandthe United States of America. Together, the Board members will contribute their innovation, technology, clinical trials and therapy expertise and insights to Venus Medtech's research, development and commercialization of ...
HANGZHOU, China,April 6, 2016/PRNewswire/ -- Venus Medtech (Hangzhou) Inc. has achieved another important milestone with its first implants inLatin America. This is the first time ever for a Chinese medical device company to bring an innovative Transcatheter Pulmonary Valve toLatin America. OnM...
"For Venus Medtech, the CE marking of VenusP-Valve™ under MDR will open a new chapter of growth in the European market", said Eric Zi, Co-Founder, Executive Director, and General Manager of the Company. "We will leverage this product to scale up our overseas revenue, ...
The first compassionate use of VenusP-Valve™ system in the US was conducted at the University of Virginia Advanced Cardiac Valve Center, US, in June 2022. Credit: Venus Medtech (Hangzhou) Inc. The VenusP-Valve™ TPVR system meets the needs of 85% of patients in the case of large ...
and General Manager of Venus Medtech. "As one of the first companies to work on transcatheter structural heart devices inChina, we have always embraced a clinical value-oriented approach to innovation. Aspiring to lead technological advances in our country, we are committed to delivering unprecedent...
"For Venus Medtech, the CE marking of VenusP-Valve™under MDR will open a new chapter of growth in the European market", said Eric Zi, Co-Founder, Executive Director, and General Manager of the Company. "We will leverage this product to scale up our overseas revenue, accelerating our ...
VenusP-ValveTM, an in-house developed novel medical device of Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as "Venus Medtech"), recently completed its first compassionate use at University of Virginia Advanced Cardiac Valve Center in t
Recently, Venus Medtech (Hangzhou) Inc. (hereinafter referred to as "Venus Medtech", 2500.HK), the leader in transcatheter structural heart valvular therapies in China, won the first prize of Technical Invention in the Outstanding Scientific Research Output Awards (Science and Technology) for High...